Skip to main content

Advertisement

SpringerLink
Log in

Androgen Deprivation Therapy and Cognitive Function in Prostate Cancer

  • Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Androgen deprivation therapy (ADT) is widely used in prostate cancer. Interest in assessing how ADT impacts cognition is growing.

Recent Findings

Studies in animals and humans suggest that androgens may affect cognitive function. However, extant studies utilizing common neurocognitive tests have not consistently demonstrated ADT-induced cognitive impairment. Retrospective analyses investigating the association between ADT and risk of dementia in large electronic patient databases have also produced conflicting results. There is only limited data on ADT-induced changes in the brain as detected by functional imaging.

Summary

It remains unclear whether cognitive deficits can occur in a patient undergoing ADT. Commonly used neurocognitive tests may not be optimal for detection of more subtle but clinically relevant cognitive impairment. While large electronic patient databases are attractive sources of information, their heterogeneity, complexity, and potential reporting biases can be a challenge. Better tools are needed to assess the cognitive impact of ADT prospectively.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cancer Stat Facts: Prostate Cancer. National Cancer Institute: Surveillance, Epidemioogy, and End Results Program. 2019. https://seer.cancer.gov/statfacts/html/prost.html Accessed 11/11/2019 2019.

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. 2019;69(1):7–34. doi:https://doi.org/10.3322/caac.21551.

  3. Liede A, Hallett DC, Hope K, Graham A, Arellano J, Shahinian VB. International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. ESMO Open. 2016;1(2):e000040. https://doi.org/10.1136/esmoopen-2016-000040.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Alibhai SM, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol. 2006;60(3):201–15. https://doi.org/10.1016/j.critrevonc.2006.06.006.

    Article  PubMed  Google Scholar 

  5. Bylow K, Mohile SG, Stadler WM, Dale W. Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review. Cancer. 2007;110(12):2604–13. https://doi.org/10.1002/cncr.23084.

    Article  CAS  PubMed  Google Scholar 

  6. Fang LC, Merrick GS, Wallner KE. Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer? Oncology (Williston Park). 2010;24(9):790–6 8.

    Google Scholar 

  7. Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol. 2006;4(9):687–96.

    PubMed  Google Scholar 

  8. Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2(4):453–61. https://doi.org/10.1001/jamaoncol.2015.4655.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kim HS, Freedland SJ. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management. Curr Opin Support Palliat Care. 2010;4(3):147–52. https://doi.org/10.1097/SPC.0b013e32833bd913.

    Article  PubMed  Google Scholar 

  10. Leahy Y. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy. Clin J Oncol Nurs. 2008;12(5):771–6. https://doi.org/10.1188/08.CJON.771-776.

    Article  PubMed  Google Scholar 

  11. Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009;70(3):235–55. https://doi.org/10.1016/j.critrevonc.2008.09.004.

    Article  PubMed  Google Scholar 

  12. Saylor PJ, Keating NL, Smith MR. Prostate Cancer Survivorship: Prevention and Treatment of the Adverse Effects of Androgen Deprivation Therapy. Journal of General Internal Medicine. 2009;24(2):389–94. https://doi.org/10.1007/s11606-009-0968-y.

  13. Sun M, Choueiri TK, Hamnvik OP, Preston MA, De Velasco G, Jiang W, et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy. JAMA Oncol. 2016;2(4):500–7. https://doi.org/10.1001/jamaoncol.2015.4917.

    Article  PubMed  Google Scholar 

  14. Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115(11):2388–99. https://doi.org/10.1002/cncr.24283.

    Article  PubMed  Google Scholar 

  15. Trost LW, Serefoglu E, Gokce A, Linder BJ, Sartor AO, Hellstrom WJG. Androgen deprivation therapy impact on quality of life and cardiovascular health. Monit Ther Replace. 2013;10(S1):84–101. https://doi.org/10.1111/jsm.12036.

    Article  CAS  Google Scholar 

  16. Wilcox A, Carnes ML, Moon TD, Tobias R, Baade H, Stamos E et al. Androgen Deprivation in Veterans with Prostate Cancer: Implications for Skeletal Health. Annals of Pharmacotherapy. 2006;40(12):2107–14. https://doi.org/10.1345/aph.1H209.

  17. Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship. Eur J Endocrinol. 2006;155(6):773–81. https://doi.org/10.1530/eje.1.02306.

    Article  CAS  PubMed  Google Scholar 

  18. Jamadar RJ, Winters MJ, Maki PM. Cognitive changes associated with ADT: a review of the literature. Asian J Androl. 2012;14(2):232–8. https://doi.org/10.1038/aja.2011.107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097–106. https://doi.org/10.1002/cncr.23658.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Joly F, Alibhai SM, Galica J, Park A, Yi QL, Wagner L, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176(6 Pt 1):2443–7. https://doi.org/10.1016/j.juro.2006.07.151.

    Article  CAS  PubMed  Google Scholar 

  21. Alibhai SM, Breunis H, Timilshina N, Marzouk S, Stewart D, Tannock I, et al. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28(34):5030–7. https://doi.org/10.1200/jco.2010.30.8742.

    Article  CAS  PubMed  Google Scholar 

  22. Cherrier MM, Rose AL, Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. J Urol. 2003;170(5):1808–11. https://doi.org/10.1097/01.ju.0000091640.59812.83.

    Article  CAS  PubMed  Google Scholar 

  23. Salminen E, Portin R, Korpela J, Backman H, Parvinen LM, Helenius H, et al. Androgen deprivation and cognition in prostate cancer. Br J Cancer. 2003;89(6):971–6. https://doi.org/10.1038/sj.bjc.6601235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Salminen EK, Portin RI, Koskinen A, Helenius H, Nurmi M. Associations between serum testosterone fall and cognitive function in prostate cancer patients. Clin Cancer Res. 2004;10(22):7575–82. https://doi.org/10.1158/1078-0432.Ccr-04-0750.

    Article  CAS  PubMed  Google Scholar 

  25. • Nead KT, Gaskin G, Chester C, Swisher-McClure S, Dudley JT, Leeper NJ, et al. Androgen deprivation therapy and future Alzheimer’s disease risk. J Clin Oncol. 2016;34(6):566–71. https://doi.org/10.1200/jco.2015.63.6266This is the first large retrospective cohort analysis using novel informatics approach to evaluate the electronic medical records of prostate cancer patients with a median follow-up period of 2.7 years. A statistically significant positive association between ADT and Alzheimer’s Disease risk was found.

    Article  CAS  PubMed  Google Scholar 

  26. Nead KT, Gaskin G, Chester C, Swisher-McClure S, Leeper NJ, Shah NH. Association between androgen deprivation therapy and risk of dementia. JAMA Oncol. 2017;3(1):49–55. https://doi.org/10.1001/jamaoncol.2016.3662.

    Article  PubMed  Google Scholar 

  27. • Baik SH, Kury FSP, McDonald CJ. Risk of Alzheimer’s disease among senior Medicare beneficiaries treated with androgen deprivation therapy for prostate cancer J Clin Oncol. 2017;35(30):3401-3409. doi:https://doi.org/10.1200/jco.2017.72.6109. This is the largest population-based cohort study to date evaluating 1.2 million fee-for-service Medicare beneficiaries with prostate cancer with a mean follow-up of 5.5 years. No meaningful effect of ADT on dementia risk was found.

  28. Lehrer S, Rheinstein PH, Rosenzweig KE. No relationship of anti-androgens to Alzheimer’s disease or cognitive disorder in the MedWatch database. J Alzheimers Dis Rep. 2018;2(1):123–7. https://doi.org/10.3233/adr-180052.

    Article  PubMed  PubMed Central  Google Scholar 

  29. • Jayadevappa R, Chhatre S, Malkowicz SB, Parikh RB, Guzzo T, Wein AJ. Association between androgen deprivation therapy use and diagnosis of dementia in men with prostate cancer. JAMA Netw Open. 2019;2(7):e196562-e. https://doi.org/10.1001/jamanetworkopen.2019.6562 JAMA Network Open. This is a large retrospective cohort study analyzing the National Cancer Institute's SEER-Medicare linked database for an association between ADT exposure and diagnosis of dementia with the longest mean follow-up of 8.3 years. ADT exposure was found to be associated with subsequent diagnosis of Alzheimer's disease or dementia.

    Article  Google Scholar 

  30. Höfer P, Lanzenberger R, Kasper S. Testosterone in the brain: neuroimaging findings and the potential role for neuropsychopharmacology. Eur Neuropsychopharmacol. 2013;23(2):79–88. https://doi.org/10.1016/j.euroneuro.2012.04.013.

    Article  CAS  PubMed  Google Scholar 

  31. K-i M, Sakamoto H, Kawata M. Androgen action in the brain and spinal cord for the regulation of male sexual behaviors. Curr Opin Pharmacol. 2008;8(6):747–51. https://doi.org/10.1016/j.coph.2008.08.010.

    Article  CAS  Google Scholar 

  32. Sarkey S, Azcoitia I, Garcia-Segura LM, Garcia-Ovejero D, DonCarlos LL. Classical androgen receptors in non-classical sites in the brain. Horm Behav. 2008;53(5):753–64. https://doi.org/10.1016/j.yhbeh.2008.02.015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Westlye LT, Kaufmann T, Alnæs D, Hullstein IR, Bjørnebekk A. Brain connectivity aberrations in anabolic-androgenic steroid users. NeuroImage Clin. 2016;13:62–9. https://doi.org/10.1016/j.nicl.2016.11.014.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Foland-Ross LC, Ross JL, Reiss AL. Androgen treatment effects on hippocampus structure in boys with Klinefelter syndrome. Psychoneuroendocrinology. 2019;100:223–8. https://doi.org/10.1016/j.psyneuen.2018.09.039.

    Article  CAS  PubMed  Google Scholar 

  35. Kenny AM, Fabregas G, Song C, Biskup B, Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. J Gerontol A Biol Sci Med Sci. 2004;59(1):M75–M8. https://doi.org/10.1093/gerona/59.1.M75.

    Article  Google Scholar 

  36. Cherrier MM. Androgens and cognitive function. J Endocrinol Investig. 2005;28(3 Suppl):65–75.

    CAS  Google Scholar 

  37. Moffat SD, Zonderman AB, Metter EJ, Kawas C, Blackman MR, Harman SM, et al. Free testosterone and risk for Alzheimer disease in older men. Neurology. 2004;62(2):188–93. https://doi.org/10.1212/WNL.62.2.188.

  38. Hsu B, Cumming RG, Waite LM, Blyth FM, Naganathan V, Le Couteur DG, et al. Longitudinal relationships between reproductive hormones and cognitive decline in older men: the Concord Health and Ageing in Men Project. J Clin Endocrinol Metab. 2015;100(6):2223–30. https://doi.org/10.1210/jc.2015-1016.

    Article  CAS  PubMed  Google Scholar 

  39. Cherrier MM, Matsumoto AM, Amory JK, Johnson M, Craft S, Peskind ER, et al. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology. 2007;32(1):72–9. https://doi.org/10.1016/j.psyneuen.2006.10.008.

    Article  CAS  PubMed  Google Scholar 

  40. Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer’s disease. Aging Male. 2003;6(1):13–7.

    Article  CAS  Google Scholar 

  41. Cherrier MM, Matsumoto AM, Amory JK, Asthana S, Bremner W, Peskind ER, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005;64(12):2063–8. https://doi.org/10.1212/01.Wnl.0000165995.98986.F1.

    Article  CAS  PubMed  Google Scholar 

  42. Lu PH, Masterman DA, Mulnard R, Cotman C, Miller B, Yaffe K, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006;63(2):177–85. https://doi.org/10.1001/archneur.63.2.nct50002.

    Article  PubMed  Google Scholar 

  43. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU International 2002;90(4):427–32. https://doi.org/10.1046/j.1464-410X.2002.02917.x.

  44. Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, et al. Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int. 2004;93(7):975–9. https://doi.org/10.1111/j.1464-410X.2004.04763.x.

    Article  CAS  PubMed  Google Scholar 

  45. Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL. Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study. BJU Int. 2005;96(1):48–53. https://doi.org/10.1111/j.1464-410X.2005.05565.x.

    Article  CAS  PubMed  Google Scholar 

  46. Almeida OP, Waterreus A, Spry N, Flicker L, Martins RN. One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men. Psychoneuroendocrinology. 2004;29(8):1071–81. https://doi.org/10.1016/j.psyneuen.2003.11.002.

    Article  CAS  PubMed  Google Scholar 

  47. • SMH A, Timilshina N, Duff-Canning S, Breunis H, Tannock IF, Naglie G, et al. Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer. Cancer. 2017;123(2):237–44. https://doi.org/10.1002/cncr.30320. This is a large prospective study evaluating 77 men with nonmetastatic prostate cancer receiving ADT for 36 months with 2 matched control groups consisting of prostate cancer patients not receiving ADT and healthy controls with neuropsychological testing. ADT for 36 months did not appear to be associated with cognitive decline.

    Article  Google Scholar 

  48. Marzouk S, Naglie G, Tomlinson G, Duff Canning S, Breunis H, Timilshina N, et al. Impact of androgen deprivation therapy on self-reported cognitive function in men with prostate cancer. J Urol. 2018;200(2):327–34. https://doi.org/10.1016/j.juro.2018.02.073.

    Article  CAS  PubMed  Google Scholar 

  49. • Gonzalez BD, Jim HS, Booth-Jones M, Small BJ, Sutton SK, Lin HY, et al. Course and predictors of cognitive function in patients with prostate cancer receiving androgen-deprivation therapy: a controlled comparison. J Clin Oncol. 2015;33(18):2021–7. https://doi.org/10.1200/jco.2014.60.1963. This is large prospective study evaluating 58 prostate cancer patients receiving 12 months of ADT and compared to prostate cancer patients without ADT and healthy controls with neuropsychological testing. Men treated with ADT were more likely to demonstrate impaired cognitive performance within 6 months after starting ADT and to continue to do so after 12 months of ADT.

  50. Morote J, Tabernero ÁJ, Álvarez Ossorio JL, Ciria JP, Domínguez-Escrig JL, Vázquez F, et al. Cognitive function in patients with prostate cancer receiving luteinizing hormone-releasing hormone analogues: a prospective, observational, multicenter study. Int J Radiat Oncol Biol Phys. 2017;98(3):590–4. https://doi.org/10.1016/j.ijrobp.2017.02.219.

    Article  PubMed  Google Scholar 

  51. Gunlusoy B, Ceylan Y, Koskderelioglu A, Gedizlioglu M, Degirmenci T, Ortan P, et al. Cognitive effects of androgen deprivation therapy in men with advanced prostate cancer. Urology. 2017;103:167–72. https://doi.org/10.1016/j.urology.2016.12.060.

    Article  PubMed  Google Scholar 

  52. Yang J, Zhong F, Qiu J, Cheng H, Wang K. Dissociation of event-based prospective memory and time-based prospective memory in patients with prostate cancer receiving androgen-deprivation therapy: a neuropsychological study 2015;24(2):198–204. doi:https://doi.org/10.1111/ecc.12299.

  53. Wu LM, Amidi A, Tanenbaum ML, Winkel G, Gordon WA, Hall SJ, et al. Computerized cognitive training in prostate cancer patients on androgen deprivation therapy: a pilot study. Support Care Cancer. 2018;26(6):1917–26. https://doi.org/10.1007/s00520-017-4026-8.

    Article  PubMed  Google Scholar 

  54. McGinty HL, Phillips KM, Jim HSL, Cessna JM, Asvat Y, Cases MG, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22(8):2271–80. https://doi.org/10.1007/s00520-014-2285-1.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Wu LM, Tanenbaum ML, Dijkers MPJM, Amidi A, Hall SJ, Penedo FJ, et al. Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: a mixed methods study. Soc Sci Med. 2016;156:80–9. https://doi.org/10.1016/j.socscimed.2016.03.016.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Lee M, Jim HS, Fishman M, Zachariah B, Heysek R, Biagioli M et al. Depressive symptomatology in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison 2015;24(4):472–7. doi:https://doi.org/10.1002/pon.3608.

  57. Donovan KA, Walker LM, Wassersug RJ, Thompson LM, Robinson JW. Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer. 2015;121(24):4286–99. https://doi.org/10.1002/cncr.29672.

    Article  CAS  PubMed  Google Scholar 

  58. Cary KC, Singla N, Cowan JE, Carroll PR, Cooperberg MR. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry. J Urol. 2014;191(4):964–70. https://doi.org/10.1016/j.juro.2013.10.098.

    Article  PubMed  Google Scholar 

  59. Mohile SG, Lacy M, Rodin M, Bylow K, Dale W, Meager MR, et al. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Crit Rev Oncol Hematol. 2010;75(2):152–9. https://doi.org/10.1016/j.critrevonc.2010.06.009.

    Article  PubMed  PubMed Central  Google Scholar 

  60. • Khosrow-Khavar F, Rej S, Yin H, Aprikian A, Azoulay L. Androgen deprivation therapy and the risk of dementia in patients with prostate cancer. J Clin Oncol. 2017;35(2):201–7. https://doi.org/10.1200/jco.2016.69.6203. This is a large retrospective cohort analysis using the United Kingdom's Clinical Practice Research Datalink evaluating the association of ADT and risk of dementia. With a mean follow-up of 4.3 years no association was found.

    Article  PubMed  Google Scholar 

  61. Chung SD, Lin HC, Tsai MC, Kao LT, Huang CY, Chen KC. Androgen deprivation therapy did not increase the risk of Alzheimer’s and Parkinson’s disease in patients with prostate cancer 2016;4(3):481–5. doi:https://doi.org/10.1111/andr.12187.

  62. Kao LT, Lin HC, Chung SD, Huang CY. No increased risk of dementia in patients receiving androgen deprivation therapy for prostate cancer: a 5-year follow-up study. Asian J Androl. 2017;19(4):414–7. https://doi.org/10.4103/1008-682x.179528.

    Article  PubMed  Google Scholar 

  63. Nead KT. Androgen deprivation therapy and dementia: new opportunities and challenges in the big-data era. J Clin Oncol. 2017;35(30):3380–1. https://doi.org/10.1200/jco.2017.74.8806.

    Article  PubMed  Google Scholar 

  64. Cherrier MM, Borghesani PR, Shelton AL, Higano CS. Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study. BMC Cancer. 2010;10:1. https://doi.org/10.1186/1471-2407-10-1.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Chao HH, Uchio E, Zhang S, Hu S, Bednarski SR, Luo X, et al. Effects of androgen deprivation on brain function in prostate cancer patients - a prospective observational cohort analysis. BMC Cancer. 2012;12:371. https://doi.org/10.1186/1471-2407-12-371.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Chao HH, Hu S, Ide JS, Uchio E, Zhang S, Rose M, et al. Effects of androgen deprivation on cerebral morphometry in prostate cancer patients – an exploratory study. PLoS One. 2013;8(8):e72032. https://doi.org/10.1371/journal.pone.0072032.

    Article  PubMed  PubMed Central  Google Scholar 

  67. • Cherrier MM, Cross DJ, Higano CS, Minoshima S. Changes in cerebral metabolic activity in men undergoing androgen deprivation therapy for non-metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(3):394–402. https://doi.org/10.1038/s41391-018-0037-x. First prospective study using PET brain imaging evaluating 9 prostate cancer patients with biochemical PSA progression. After 9 months of complete ADT with leuprolide and flutamide PET scans revealed decreased regional cerebral glucose metabolism in the cerebellum, posterior cingulate, and medial thalamus bilaterally. Brain regions were reportedly impacted by ADT that overlap with brain regions with metabolic decline found in early AD and diabetes.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, et al. Cognitive impairment in men with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2018;199(6):1417–25. https://doi.org/10.1016/j.juro.2017.11.136.

    Article  PubMed  Google Scholar 

  69. Boyle HJ, Alibhai S, Decoster L, Efstathiou E, Fizazi K, Mottet N, et al. Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer. 2019;116:116–36. https://doi.org/10.1016/j.ejca.2019.04.031.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work is supported by grants R01CA218501 and 1I01 CX001301-01A2 to HHC.

Author information

Authors and Affiliations

  1. Yale University School of Medicine, 367 Cedar Street, New Haven, CT, 06510, USA

    Jonathan Kluger

  2. Yale Comprehensive Cancer Center & VA Connecticut Healthcare System, 950 Campbell Avenue, West Haven, CT, 06516, USA

    Alicia Roy & Herta H. Chao

Authors
  1. Jonathan Kluger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alicia Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Herta H. Chao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Herta H. Chao.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors except for references [65] and [66]. Studies cited in references [65] and [66] were approved by the Yale Human Investigation Committee and the Human Investigation Subcommittee of the Veterans Affairs Connecticut Healthcare System. All participants signed informed consent.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Genitourinary Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kluger, J., Roy, A. & Chao, H.H. Androgen Deprivation Therapy and Cognitive Function in Prostate Cancer. Curr Oncol Rep 22, 24 (2020). https://doi.org/10.1007/s11912-020-0884-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-020-0884-1

Keywords

Search

Navigation